Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;44(3):332-339.
doi: 10.1002/clc.23530. Epub 2021 Jan 27.

Clinical significance of coronavirus disease 2019 in hospitalized patients with myocardial injury

Michael Briscoe  1 , Robert Sykes  2   3 , Thomas Krystofiak  1 , Oliver Peck  1   3 , Kenneth Mangion  1   2   3 , Colin Berry  1   2   3
Affiliations

Clinical significance of coronavirus disease 2019 in hospitalized patients with myocardial injury

Michael Briscoe et al. Clin Cardiol. 2021 Mar.

Abstract

Background: The clinical significance of Coronavirus disease 2019 (COVID-19) as an associate of myocardial injury is controversial.

Hypothesis: Type 2 MI/Myocardial Injury are associated with worse outcomes if complicated by COVID-19.

Methods: This longitudinal cohort study involved consecutive patients admitted to a large urban hospital. Myocardial injury was determined using laboratory records as ≥1 hs-TnI result >99th percentile (male: >34 ng/L; female: >16 ng/L). Endotypes were defined according to the Fourth Universal Definition of Myocardial Infarction (MI) and COVID-19 determined using PCR. Outcomes of patients with myocardial injury with and without COVID-19 were assessed.

Results: Of 346 hospitalized patients with elevated hs-TnI, 35 (10.1%) had laboratory-confirmed COVID-19 (median age [IQR]; 65 [59-74]; 64.8% male vs. COVID-19 negative: 74 [63-83] years; 43.7% male). Cardiac endotypes by COVID-19 status (yes vs. no) were: Type 1 MI (0 [0%] vs. 115 [100%]; p < .0005), Type 2 MI (13 [16.5%] vs. 66 [83.5%]; p = .045), and non-ischemic myocardial injury (cardiac: 4 [5.8%] vs. 65 [94.2%]; p = .191, non-cardiac:19 [22.9%] vs. 64 [77.%]; p < .0005). COVID-19 patients had less comorbidity (median [IQR] Charlson Comorbidity Index: 3.0 [3.0] vs. 5.0 [4.0]; p = .001), similar hs-TnI concentrations (median [IQR] initial: 46 [113] vs. 62 [138]; p = .199, peak: 122 [474] vs. 79 [220] ng/L; p = .564), longer admission (days) (median [IQR]: 14[19] vs. 6[12]; p = .001) and higher in-hospital mortality (63.9% vs. 11.3%; OR = 13.2; 95%CI: 5.90, 29.7).

Conclusions: Cardiac sequelae of COVID-19 typically manifest as Non-cardiac myocardial injury/Type 2MI in younger patients with less co-morbidity. Paradoxically, the admission duration and in-hospital mortality are increased.

Keywords: COVID-19; Type 2 myocardial infarction; coronavirus; myocardial Injury; outcomes; troponin.

PubMed Disclaimer

Conflict of interest statement

Colin Berry is employed by the University of Glasgow, which holds consultancy and research agreements with companies that have interests in the diagnosis and treatment of angina. The companies include Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Coroventis, GSK, HeartFlow, Medyria, Neovasc, Novartis and Siemens Healthcare.

The authors declare no potential conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Flow diagram
FIGURE 2
FIGURE 2
Proportion of cardiovascular causes of myocardial injury in COVID‐19 positive (A; n = 4) and negative (B; n = 65) patients
FIGURE 3
FIGURE 3
Proportion of Type 2 MI and non‐cardiac of myocardial injury in COVID‐19 positive (A; n = 32) and negative (B; n = 130) patients
See this image and copyright information in PMC

References

    1. Jaffe AS, Cleland JGF, Katus HA. Myocardial injury in severe COVID‐19 infection. Eur Heart J. 2020;41(22):2080‐2082. - PMC - PubMed
    1. Shaobo S, Qin M, Cai Y, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020;41:2070‐2079. - PMC - PubMed
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054‐1062. - PMC - PubMed
    1. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID‐19 and cardiovascular disease. Circulation. 2020;141:1648‐1655. - PubMed
    1. Mangion K, Morrow A, Bagot C, et al. The Chief Scientist Office cardiovascular and pulmonary imaging in SARS coronavirus disease‐19 (CISCO‐19) study. Cardiovasc Res. 2020;116(14):2185‐2196. - PMC - PubMed